Latest News and Press Releases

WOODLAND HILLS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative...

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...

AVTALET LIGGER I LINJE MED KLINISK UTVECKLINGSSTRATEGI FÖR DCP-001 Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som adresserar tumöråterfall, har idag...

TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today...

INFORMATION REGLEMENTEE Link Health recevra les droits mondiaux pour le développement, la fabrication et la commercialisation d'ALLOB. Bone Therapeutics sera éligible dès la...

REGULATED INFORMATION Link Health to be granted global rights for development, manufacturing and commercialization of ALLOB Bone Therapeutics to receive R&D cost reimbursement,...

Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP...